Unjha Formulations Reports Declining Financial Metrics, Signaling Ongoing Revenue Challenges in March 2025

Unjha Formulations, a microcap player in the Pharmaceuticals & Biotechnology sector, has recently reported its financial results for the quarter ending March 2025. The results indicate a challenging period for the company, with notable shifts in its financial metrics.
Net sales for the latest six months reached Rs 6.13 crore, reflecting a year-on-year contraction. This trend suggests ongoing difficulties in generating revenue. Additionally, the operating profit (PBDIT) has recorded its lowest figure in the last five quarters, standing at Rs -0.33 crore, indicating a persistent struggle in maintaining profitability. Similarly, the profit before tax (PBT) has also hit a low of Rs -0.36 crore during the same period, further emphasizing the challenges faced by the company.

Earnings per share (EPS) have declined to Rs -0.92, marking the lowest level in five quarters and highlighting a decrease in profitability for shareholders. These financial results have led to an adjustment in evaluation for Unjha Formulations, reflecting the current state of the company's performance.

For more insights, you can Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.